Half-year revenue up 45%, profit after tax up 31%; margin narrows

Revenue Growth 20pctPat Growth 25pctEbitda Margin CompressionResults View source PDF Explain this filing

BAJAJHCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.1%Reaction day

₹470.00

prior close

₹471.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.0%-3.1% vs market

Pharmaceuticals peers, median of 153sector+0.3%-2.4% vs sector

On the reaction day the stock moved 3.1 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-1.7

15m

-1.3

30m

-1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.1+1.0-3.1+0.3-2.4

Next day

-3.4+2.0-5.4+0.9-4.3

-4.3+1.6-5.8+0.6-4.9

-2.8+1.2-4.1+0.3-3.1

-3.6+1.6-5.2+0.3-3.9

-3.6+1.9-5.4+0.1-3.7

+2.6+2.1+0.4+0.6+1.9

15d

-4.4+1.0-5.4-1.0-3.4

-8.5+0.2-8.7-1.9-6.6

-10.6-3.1-7.5-4.1-6.5

-21.3-10.9-10.4-11.9-9.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The board approved unaudited results. Quarter revenue rose 13% to Rs 147.01 crore and profit after tax was about Rs 11.1 crore, up about 17%. For the half year, revenue increased 45% to Rs 296.75 crore and profit after tax rose 31% to Rs 22.04 crore. Operating cash flow was positive at Rs 50.19 crore. The half-year margin before depreciation and financing fell from 25.8% to 18.2%.

Likely market impact

Half-year growth and strong cash generation support sentiment, but the lower margin may limit the stock's upside.